The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase 1a/1b study of LB-LR1109, an anti-LILRB1 monoclonal antibody, as monotherapy in advanced solid tumors and in combination with atezolizumab in advanced NSCLC.
 
Hyungjin Cho
Employment - LG Chem
 
Subin Wang
Employment - LG Chem Lifesciences
 
Jawon Kim
Employment - LG Chem Lifesciences
 
Taekyeong Yoo
Employment - LG Chem Lifesciences
 
SoLa Park
Employment - LG Chem Lifesciences
 
Jiyeon Ryu
Employment - LG Chem Lifesciences
 
Bhumsuk Keam
Honoraria - MSD Oncology
Consulting or Advisory Role - AVEO; Bicara Therapeutics; Handok; TiumBio; Trial Informatics; Yuhan
Research Funding - AstraZeneca; Bayer
 
Se Hyun Kim
No Relationships to Disclose
 
Se Hoon Park
Honoraria - Merck; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Janssen Oncology
Research Funding - Merck Sharp & Dohme LLC (Inst)
 
Jae Lyun Lee
Stock and Other Ownership Interests - Amgen; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Merck; Zymeworks
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Merck; Novartis
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Eutilex (Inst); GI Innovation (Inst); Janssen (Inst); LG Chem (Inst); Loxo/Lilly (Inst); Merck KGaA (Inst); MSD (Inst); Novartis (Inst); Oscotec (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Ji-Youn Han
Honoraria - AstraZeneca; Janssen; Merck; Novartis; Pfizer; Takeda; Yuhan
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Daiichi Sankyo/UCB Japan; Janssen; Merck; Novartis
Research Funding - Pfizer; Roche
 
Cesar Perez
Consulting or Advisory Role - BeiGene; Ipsen; Pfizer
Research Funding - Accutar Biotech (Inst); ADANATE Biotechnology (Inst); Avenzo Therapeutics (Inst); Avenzo Therapeutics (Inst); BeiGene (Inst); Coherent Biopharma (Inst); Coherus Biosciences (Inst); Compass Therapeutics (Inst); Corvus Pharmaceuticals (Inst); DualityBio (Inst); Elevation Oncology (Inst); Exelixis (Inst); Genentech (Inst); Kura Oncology (Inst); Loxo/Lilly (Inst); Menarini (Inst); Merus (Inst); Mirati Therapeutics (Inst); NextCure (Inst); PDS Biotechnology (Inst); Pfizer (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Systimmune (Inst); Tachyon Therapeutics (Inst); Tallac Therapeutics (Inst); Torl Biotherapeutics (Inst); Xilio Therapeutics (Inst); Zhuhai Yufan Biotechnologies (Inst)
 
Alex Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Lilly; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); crispr therapeutics; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Revolution Medicines; Sanofi; Sanofi; Synthekine; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; lepu biopharma (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Tango Therapeutics (Inst)
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; BeOne; Daiichi Sankyo; Eisai; indivumed; LG Chem; MSD Oncology; Ono Pharmaceutical; Toray Industries
Speakers' Bureau - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; BeOne; BMS/Ono; Daiichi Sankyo/UCB Japan; Eisai; MSD Oncology
Research Funding - Amgen (Inst); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BeOne (Inst); Beringer Ingelheim (Inst); Bristol-Myers Squibb; Daichii Sankyo; Eisai; Indivumed; Jazz Pharmaceuticals (Inst); Lilly; MSD Oncology; Roche/Genentech; Sillajen